Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124713262 | 12471326 | 2 | F | 20160614 | 20160616 | 20160707 | PER | US-PFIZER INC-2016285616 | PFIZER | 80.00 | YR | F | Y | 0.00000 | 20160707 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124713262 | 12471326 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 300 MG, DAILY | U | 20235 | 300 | MG | |||||||
| 124713262 | 12471326 | 2 | SS | HORIZANT | GABAPENTIN ENACARBIL | 1 | Oral | 300 MG, DAILY | 0 | 300 | MG | ||||||||
| 124713262 | 12471326 | 3 | SS | HORIZANT | GABAPENTIN ENACARBIL | 1 | Oral | 600 MG, DAILY | 0 | 600 | MG | ||||||||
| 124713262 | 12471326 | 4 | SS | HORIZANT | GABAPENTIN ENACARBIL | 1 | 0 | ||||||||||||
| 124713262 | 12471326 | 5 | C | ATENOLOL. | ATENOLOL | 1 | UNK | 0 | |||||||||||
| 124713262 | 12471326 | 6 | C | LISINOPRIL. | LISINOPRIL | 1 | UNK | 0 | |||||||||||
| 124713262 | 12471326 | 7 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | UNK | 0 | |||||||||||
| 124713262 | 12471326 | 8 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | UNK | 0 | |||||||||||
| 124713262 | 12471326 | 9 | C | PROBIOTIC | PROBIOTICS NOS | 1 | UNK | 0 | |||||||||||
| 124713262 | 12471326 | 10 | C | VITAMIN C | ASCORBIC ACID | 1 | UNK | 0 | |||||||||||
| 124713262 | 12471326 | 11 | C | CURCUMIN | CURCUMIN | 1 | UNK | 0 | |||||||||||
| 124713262 | 12471326 | 12 | C | COQ10 | UBIDECARENONE | 1 | UNK | 0 | |||||||||||
| 124713262 | 12471326 | 13 | C | ZINC | ZINCINC CHLORIDE | 1 | UNK | 0 | |||||||||||
| 124713262 | 12471326 | 14 | C | MB COMPLEX | 2 | UNK | 0 | ||||||||||||
| 124713262 | 12471326 | 15 | C | KRILL OIL | DIETARY SUPPLEMENT | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124713262 | 12471326 | 1 | Neuropathy peripheral |
| 124713262 | 12471326 | 2 | Neuropathy peripheral |
| 124713262 | 12471326 | 3 | Paraesthesia |
| 124713262 | 12471326 | 4 | Pain |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124713262 | 12471326 | Depression | |
| 124713262 | 12471326 | Feeling abnormal | |
| 124713262 | 12471326 | Headache | |
| 124713262 | 12471326 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124713262 | 12471326 | 3 | 20160524 | 20160527 | 0 |